ÖYÖmer Aydın Yıldırım

Ömer Aydın Yıldırım

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ömer Aydın Yıldırım has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • REAL-WORLD OUTCOMES OF SECOND- AND THIRD-LINE THERAPIES AFTER FIRST-LINE VEGFR-TKI FAILURE IN METASTATIC RENAL CELL CARCINOMA: A SINGLE-CENTER EXPERIENCE FROM TÜRKİYE

    by Beril Balcı Topuz, Ahmet Tüfekçi, Sibel Cangi, Ömer Aydın Yıldırım, Mustafa Yıldırım

    Objective: Immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have transformed the treatment of metastatic renal cell carcinoma (mRCC), yet access limitations continue to shape real-world practice. This study evaluated the outcomes of second- and third-line systemic therapies administered after TKI failure within a single-center cohort.Materials and methods: This retrospective study included 50 patients with histologically confirmed mRCC treated between 2014 and 2024. Eligible patients had received at least one line of TKI therapy and subsequently received second-line nivolumab or axitinib. Survival outcomes were analyzed using Kaplan – Meier and log-rank tests.Results: The median age was 63 years; 76% were International Metastatic RCC Database Consortium intermediate-risk, and 82% had undergone nephrectomy. First-line therapy consisted of sunitinib (72%) or pazopanib (28%), with a median progression-free survival (PFS) of 7 months. In the second line, 40 patients (80%) received nivolumab and 10 (20%) axitinib. Median PFS and OS were 10 and 20 months for nivolumab vs. 4 and 5 months for axitinib (both p0.05). Five patients (four axitinib and one cabozantinib) were alive at the last follow-up.Conclusion: In this cohort, nivolumab was associated with longer PFS and OS compared to axitinib in the second-line setting after TKI failure, whereas axitinib and cabozantinib demonstrated similar outcomes in the third-line setting.

  • Open Access

    The C-Reactive Protein–Albumin–Lymphocyte (CALLY) Index as an Independent Predictor of Progression and Survival in Metastatic Renal Cell Carcinoma

    by Beril Balci Topuz, Ahmet Tufekci, Sibel Cangi, Omer Aydin Yildirim, Mustafa Yildirim

    Background/Objectives: Systemic inflammation, nutritional status, and immune competence have emerged as important prognostic determinants in metastatic renal cell carcinoma (mRCC). The C-reactive protein–albumin–lymphocyte (CALLY) index integrates these parameters into a single composite biomarker, yet its utility in mRCC remains insufficiently explored. This study aimed to evaluate the prognostic significance of the CALLY index in mRCC and its associations with clinicopathological features and survival outcomes. Methods: A total of 68 patients with mRCC treated between 2017 and 2024 were retrospectively analyzed. All patients received first-line VEGF–TKI therapy, and 73.5% subsequently received second-line treatment, predominantly nivolumab. The CALLY index was calculated as (albumin × lymphocyte count)/(CRP × 104), and patients were stratified using the median cut-off (0.16). Survival outcomes were assessed with Kaplan–Meier and Cox regression analyses. Discriminative performance was evaluated using Harrell’s C-index and time-dependent ROC curves at 6, 12, and 24 months. Results: Low CALLY (≤0.16) was significantly associated with shorter PFS (4 vs. 8 months, p < 0.001) and OS (9 vs. 26 months, p < 0.001). In multivariate analysis, the CALLY index independently predicted both PFS (HR = 1.91, p = 0.045) and OS (HR = 2.89, p = 0.005). Time-dependent ROC analysis demonstrated increasing discriminative strength for PFS (AUC: 0.70 → 0.95) and modest decline for OS over time (AUC: 0.83 → 0.72). CALLY also showed strong associations with IMDC risk classification and peritoneal metastasis. Conclusions: The CALLY index is a simple, cost-effective, and objective prognostic biomarker that may independently predict progression and survival in mRCC. Its complementary value to the IMDC model supports its integration into routine risk stratification and real-world clinical decision-making.


  • Open Access

    HMBG-1: A Biomarker in the Management of Diabetic Retinopathy

    by Burak Bilgin, Necla Benlier, Ömer Aydın Yıldırım, Fatih Özbakış, Nuri Orhan, Nihal Cesur Özbakış, Hüseyin Gürbüz

    Introduction: High mobility group box (HMGB)-1 protein is a promising prognostic marker for predicting the course of retinopathy and the prognosis in patients with diabetic retinopathy (DR). The aim of this study is to investigate whether serum HMGB-1 protein levels can be used as a biomarker about the severity of the disease in patients with diabetic retinopathy. Material and methods: This study was carried out in the internal medicine and ophthalmology departments of the Gaziantep Medicalpark Hospital. The records of 50 patients diagnosed with type 2 diabetes mellitus with diabetic retinopathy and 47 healthy subjects who applied to our clinic between January 2016 and December 2018 were retrospectively scanned. Five cc of venous blood was taken from the patients, and control groups were included in the study for routine laboratory tests and serum HMGB-1 levels to be studied under appropriate conditions. Human HMGB-1 levels were measured using the ELISA method. Results: There was a significant difference among the groups in terms of HMGB-1 levels (p<0.001) (Table-1). There was a positive correlation between blood glucose and HMGB-1 in the diabetic retinopathy group (Spearman's rho (ρ)=0.07). Similarly, there was a positive correlation between HbA1c and HMGB-1 levels in the diabetic retinopathy group. (Spearman's rho (ρ)=0.06). Conclusions: Our study suggests that HMGB-1 may be a useful biomarker in managing DR, aiding in the prediction and treatment of microvascular complications.